Regardless of the FGFR2 status, premenopausal vs. postmenopausal patients were more frequently linked with lymph node metastases (P = 0.023), presence of DCIS component (P = 0.001) and chemotherapy in the adjuvant setting (P = 0.006). Here, FGFR2 is linked to metastatic malignant neoplasm in the lymph nodes.